This year thus far has seen several high-profile deals and expansion moves in the contract development and manufacturing sector for drug products. So what moves should be on your radar?…
GSK’s CEO Highlights Strategic Priorities in Strengthening Pharmaceutical Business
Emma Walmsley, who became CEO of GlaxoSmithKline (GSK) on April 1, highlighted the priorities of the company following its first-half 2017 results. So what may be in store for GSK?…
Pharmaceutical industry leaders are calling for an orderly implementation relating to the regulation, manufacture, and supply of medicines post Brexit. So what are their chief concerns? The chief executives from…
Johnson &Johnson’s $30-billion buy of Actelion is the leading deal thus far in 2017, but what other deals have made the mark? The supplier side adds to important deals: Thermo…
J&J’s $30-Billion Buy of Actelion: What Does It Mean for J&J?
Johnson & Johnson (J&J) has completed its $30-billion acquisition of the Swiss pharmaceutical company, Actelion. So what is the impact for J&J? The move provides J&J with a specialist in…
A recent study by Deloitte surveyed C-suite executives to better understand how they view their organizations’ capabilities in balancing risk and reward. The study showed an abundance of confidence in…
Emma Walmsley, who became CEO of GlaxoSmithKline (GSK) on April 1, is leading a company that is seeking to get better returns from its pharmaceutical business. So what may be…
Which drugs entering the market are poised as blockbusters? DCAT Value Chain Insights examines the contenders for this year. A recent analysis by Clarivate Analytics points to nine drugs entering…
Potential mega-mergers put Pfizer in the headlines over the past several years, but will that be the strategy of the company going forward? DCAT Value Chain Insights takes an inside…
From healthcare reform, to slowing global pharmaceutical industry growth, to a possible showdown in biosimilars, DCAT Value Chain Insights examines the top 10 items that should be on your pharmaceutical…
